[1]江梦颖,姜戈晨,张欣怡,等.新型冠状病毒肺炎与血浆输注治疗[J].镇江高专学报,2020,33(03):109-112.
 JIANG Mengying,JIANG Gechen,ZHANG Xinyi,et al.Coronavirus disease 2019 and plasma infusion therapy[J].Journal of Zhenjiang College,2020,33(03):109-112.
点击复制

新型冠状病毒肺炎与血浆输注治疗()
分享到:

《镇江高专学报》[ISSN:/CN:]

卷:
33
期数:
2020年03期
页码:
109-112
栏目:
中学教学研究
出版日期:
2020-07-31

文章信息/Info

Title:
Coronavirus disease 2019 and plasma infusion therapy
文章编号:
1008-8148 (2020)03-0109-04
作者:
江梦颖姜戈晨张欣怡吕云玮孙晓春*
(江苏大学 医学院,江苏 镇江212013)
Author(s):
JIANG Mengying JIANG Gechen ZHANG Xinyi LYU Yunwei SUN Xiaochun*
(School of Medicine, Jiangsu University, Zhenjiang 212013, China)
关键词:
血浆输注新型冠状病毒新冠肺炎
Keywords:
plasma therapy coronavirus disease 2019 COVID19
分类号:
R563
文献标志码:
A
摘要:
自2019年12月起,新型冠状病毒肺炎(COVID19)的爆发扰乱了中国的社会秩序。目前该病已被世界卫生组织(WHO)评估为世界范围内的大流行病。截至2020年3月13日,已经有123个国家和地区向世卫组织报告了13.2万COVID19病例,死亡人数超过5 000。目前在缺乏疫苗和特效治疗药物的情况下,采用特异性免疫血浆制品治疗COVID19是最为有效的方法,可大幅降低危重症患者病死率。与此同时,血浆治疗仍有许多待解决的问题,解决这些问题有助于更好地治疗重症患者。
Abstract:
The outbreak of coronavirus disease 2019 (COVID19) has disrupted Chinas social order since December 2019. At present, the disease has been assessed as a worldwide pandemic by the World Health Organization (WHO). Up to March 13, 2020, 123 countries and regions have reported more than 132,000 COVID19 cases to WHO, and the death toll has exceeded 5,000. At present, in the absence of vaccines and specific therapeutic drugs, the use of specific immune plasma products in the treatment of the COVID19 is the most effective method, which can significantly reduce the mortality of critically severe patients. At the same time, there are still many problems to be solved in plasma therapy, and the solving of these problems will help to better treat critically severe patients.

参考文献/References:

[1].\[1\] 邱晨辉.“血浆疗法”背后的科学原理\[EB/OL\].(2020-03-13)\[2020-03-15\].http://www.chinanews.com/m/gn/2020/03-10/9119699.shtml.
[2].\[2\] 国家卫生健康委员会办公厅.新型冠状病毒肺炎诊疗方案(试行第七版)\[EB/OL\].(2020-03-04)\[2020-03-15\].http://www.nhc.gov.cn/yzygj/s76 53p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[3].\[3\] ZHU N, ZHANG D Y, WANG W L, et al. A novel coronavirus from patients with pneumonia in China, 2019\[J\].New England Journal of Medicine ,2020,382(8):727-733.
[4].\[4\] RIDER T H, ZOOK C E, BOETTCHER T L, et al. Broadspectrum antiviral therapeutics\[J\].PLOS ONE,2011,6(7):e22572.
[5].\[5\] 刘广洋,郑力搏,王皓,等.间充质干细胞治疗新型冠状病毒肺炎的研究\[J\].药物评价研究,2020,43(3):372-377.
[6].\[6\] 国家卫生健康委员会办公厅.新冠肺炎康复者恢复期血浆临床治疗方案(试行第二版)\[EB/OL\].(2020-03-04)\[2020-03-15\].http://www.nhc.gov.cn/yzygj/s7658/202003/61d608a7e8bf49fca418a6074 c2bf5a2.shtml.
[7].\[7\] 高钰琪.基于新冠肺炎病理生理机制的治疗策略\[J\].中国病理生理杂志,2020,36(3):568-572,576.
[8].\[8\] BUCHWALD U K, PIROFSKI L. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future roleof antibody therapy, therapeutic vaccination and biological response modifiers\[J\].Current Pharmaceutical Design ,2003,9(12):945-968.
[9].\[9\] World Health Organization, Blood Regulators Network. Position paper on collection and use of convalescent plasma or serum as an element in pandemic influenza planning \[EB/OL\].(2016-06-15)\[2020-03-15\]. http://www.who.int/bloodproducts/brn/en/.
[10].\[10\] 王学文.血浆疗法在血栓性血小板减少性紫癜中的应用\[J\].肾脏病与透析肾移植杂志,2004(6):572-575.
[11].\[11\] 刘小荣.溶血尿毒综合征的诊治进展\[J\].中华肾病研究电子杂志,2016,5(2):61-64.
[12].\[12\] 张婕,夏正坤,刘光陵.非典型溶血尿毒综合征发病机制和治疗研究进展\[J\].临床儿科杂志,2012,30(4):393-396.
[13].\[13\] 王妙淑.新鲜冰冻血浆治疗重度有机磷农药中毒的临床研究\[J\].实用医学杂志,2011,27(11):1970-1971.
[14].\[14\] 宋知仁,郑建锋,赵香莲,等.外用新鲜冷冻血浆治疗烧伤残余创面的临床观察\[J\].中华损伤与修复杂志(电子版),2015,10(4):325-328.
[15].\[15\] 白茹,张艳秋.新鲜血浆治疗小儿肺炎的疗效分析\[J\].中国卫生工程学,2010,9(S1):52.
[16].\[16\] 栾禄君,常曙薇,王文余,等.联合抗过敏加输新鲜血浆治疗流行性出血热后期病人537例疗效观察\[J\].中国免疫学杂志,1996,2:130-132.
[17].\[17\] 王爱军,李广平,张瑞椿.中心静脉导管腹腔置管联合新鲜血浆治疗肝硬化顽固性腹水对肝肾功能影响\[J\].中外医疗,2013,32(4):103-104.
[18].\[18\] MAIRJENKINS J, SAAVEDRACAMPOS M, BAILLIE J K, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta analysis \[J\].Journal of Infectious Diseases,2015,211(1):80-90.
[19].\[19\] 杨晓明,侯继峰.康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景\[J\].中国生物制品学杂志,2020,33(3):241-245.
[20].\[20\] 张雅婷.科技部:恢复期血浆疗法安全有效已有患者出院,呼吁康复者献血浆\[EB/OL\].(2020-02-17)\[2020-03-16\].https://www.sohu.com/a/373704957_161795.
[21].\[21\] BACKER J A, KLINKENBERG D, WALLINGA J. The incubation period of 2019-nCoV infections among travellers from Wuhan, China\[J\].Eurosurveillance ,2020,25(5):2000062.
[22].\[22\] CHAN J F, YUAN S F, KOK K H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating persontoperson transmission: a study of a family cluster\[J\].The Lancet,2020,395(10223):514-523.
[23].\[23\] World Health Organization. WHO Recommendations on SARS and Blood \[EB/OL\].(2013-05-15)\[2020-03-10\].http://www.who.int/csr/sars/guidelines/blood safety/en/.
[24].\[24\] 国家卫生健康委员会.《关于做好新型冠状病毒肺炎疫情期间血液安全供应保障工作的通知》解读\[EB/OL\].(2020-02-10)\[2020-03-09\].http://www.xinhuanet.com/health/2020-02/11/c_1125557232.htm.
[25].\[25\] 张评,高国静,蔡峥,等.SARS流行期间北京市临床供血的管理\[J\].中华医院感染学杂志,2004,14(9):1029-1030.
[26].\[26\] 林新天,罗文华,杜建文,等.珠海市医疗用血现状及其对策\[J\].广东药学院学报,2001,17(2):153-154.
[27].\[27\] YEH K M, CHIUEH T S, SIU L K, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital\[J\].Journal of Antimicrobial Chemotherapy,2005,56(5):919-922.

备注/Memo

备注/Memo:
收稿日期: 2020-03-19?
作者简介: 江梦颖(1998—),女,江苏淮安人,主要从事输血安全研究;姜戈晨(1998—),女,江苏淮安人,主要从事输血安全研究。*为通讯作者。
更新日期/Last Update: 2020-09-20